<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489592</url>
  </required_header>
  <id_info>
    <org_study_id>C11-14</org_study_id>
    <secondary_id>2011-001925-26</secondary_id>
    <nct_id>NCT01489592</nct_id>
  </id_info>
  <brief_title>Effect of Curcumin on Iron Metabolism in Healthy Volunteer</brief_title>
  <acronym>CURHEP</acronym>
  <official_title>Effect of Curcumin on Iron Metabolism in Healthy Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the impact of curcumin, administrated orally, on
      iron metabolism in healthy volunteers. Iron metabolism will be describe by hepcidin
      expression that the investigators observed in vitro and serum hepcidin levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal variation of serum hepcidin level after oral administration of curcumin</measure>
    <time_frame>within 48 hours after administration of curcumin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasmatic iron bioavailability</measure>
    <time_frame>30min, 1H, 2H, 3H, 4H, 6H, 8H, 12H, 24H et 48H</time_frame>
    <description>Iron, ferritin, transferrin, transferrin saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the inhibitory activity of volunteers's serum on hepcidin expression by hepatocytes</measure>
    <time_frame>30min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h</time_frame>
    <description>In vitro:
the coculture model that we previously developed to analyze endogenous hepcidin expression, and
human hepatic cells line (HepG2) stimulated or not by IL-6 which governs the STAT3 pathway, transfected with gene reporter constructs containing hepcidin promoter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of 6g of curcumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral administration of 12 sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>curcuma longa</intervention_name>
    <description>oral administration of 6 grams of curcumin</description>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 18 et 25 Kg/m²

          -  Non smoker

          -  No swallowing disorders

          -  Normal clinical exam

          -  Normal ECG

          -  Normal values for routine biological tests : serum iron, transferrin saturation,,
             hemogram ferritin, C Reactive Protein, AST, ALT, HDL and LDL cholesterol,
             triglycerides

          -  No C282Y mutation within the HFE gene

          -  Affiliation to social security

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Chronic or evolutive disease

          -  Infection during the 7 days before each sequence

          -  Drug or alcohol (&gt;30g) abuse

          -  Current treatment

          -  Known food allergy

          -  stay at altitude (&gt; 1500m) in 2 months

          -  Positive serology for hepatitis B or C virus or HIV.

          -  Transfusion or blood donation during the last three months.

          -  Exclusion period on the healthy volunteer National File.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique (CIC) , 2 rue Henri Le Guilloux , CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Fatih N, Camberlein E, Island ML, Corlu A, Abgueguen E, Détivaud L, Leroyer P, Brissot P, Loréal O. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010 May;88(5):477-86. doi: 10.1007/s00109-009-0588-3. Epub 2010 Feb 19.</citation>
    <PMID>20169331</PMID>
  </reference>
  <reference>
    <citation>Loréal O, Haziza-Pigeon C, Troadec MB, Detivaud L, Turlin B, Courselaud B, Ilyin G, Brissot P. Hepcidin in iron metabolism. Curr Protein Pept Sci. 2005 Jun;6(3):279-91. Review.</citation>
    <PMID>15974953</PMID>
  </reference>
  <reference>
    <citation>Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007 Jan 1;109(1):353-8. Epub 2006 Aug 31.</citation>
    <PMID>16946298</PMID>
  </reference>
  <reference>
    <citation>Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004 Oct 15;10(20):6847-54.</citation>
    <PMID>15501961</PMID>
  </reference>
  <reference>
    <citation>Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7. doi: 10.1158/1055-9965.EPI-07-2693.</citation>
    <PMID>18559556</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

